An Assay for Screening of Heparin-Induced Thrombocytopenia An Assay for Screening of Heparin-Induced Thrombocytopenia
This study evaluated the usefulness of an alternative assay, the PIFA PLUSS P4, as a rapid screening test for the diagnosis of heparin-induced thrombocytopenia.Laboratory Medicine
Early detection of Primary Immunodeficiencies Disorders (PIDDs) is of paramount importance for effective treatment and disease management. Many PIDDs would be strong candidates for newborn screening (NBS) if robust screening methods could identify patients from dried blood spots (DBS) during the neonatal period. As majority of congenital PIDDs result in the reduction or absence of specific proteins, direct quantification of these target proteins represents an attractive potential screening tool. Unfortunately, detection is often limited by the extremely low protein concentrations in blood cells and limited blood volume pre...
Optimal intraoperative anticoagulation strategy for patients with heparin-induced thrombocytopenia (HIT) undergoing pulmonary thromboendarterectomy (PTE) that necessitates deep hypothermic circulatory arrest (DHCA) remains controversial. Cangrelor is an intravenous direct-acting P2Y12 platelet receptor antagonist that achieves therapeutic effect and eliminates rapidly. Its antiplatelet activity is unaffected by stagnation of blood, nor is it influenced by patient's age, renal status or hepatic function.
Verotoxin, VT (aka Shiga toxin,Stx) is produced by enterohemorrhagic E. coli (EHEC) and is the key pathogenic factor in EHEC-induced hemolytic uremic syndrome (eHUS-hemolytic anemia/thrombocytopenia/glomerular infarct) which can follow gastrointestinal EHEC infection, particularly in children. This AB5 subunit toxin family bind target cell globotriaosyl ceramide (Gb3), a glycosphingolipid (GSL) (aka CD77, pk blood group antigen) of the globoseries of neutral GSLs, initiating lipid raft-dependent plasma membrane Gb3 clustering, membrane curvature, invagination, scission, endosomal trafficking, and retrograde traffic via the...
Authors: Kounis NG, Koniari I, Soufras GD, Tsigkas G, Plotas P, Davlouros P, Hahalis G PMID: 32214073 [PubMed - as supplied by publisher]
Immune checkpoint inhibitors (ICIs) have been extensively investigated as a novel form of cancer therapy against a range of malignancies including urothelial carcinoma . Notably however, they have also been associated with unique toxicities known as immune-related adverse events (irAEs) which may involve any organs, including haematologic systems . The precise mechanisms involved in different irAEs are largely unknown, but they are believed to be associated with aberrant activation of immune systems induced by ICIs.
Condition: Low/Intermediate Risk-1 MDS Interventions: Drug: Danazol + rhTPO (recombinant human thrombopoietin injection); Drug: Danazol + sodium chloride Sponsor: Peking Union Medical College Hospital Active, not recruiting
Abstract BACKGROUND: A standard approach to the recognition and management of major bleeding in immune thrombocytopenia (ITP) is lacking. METHODS: Retrospective cohort study of ITP patients presenting to the ED with severe thrombocytopenia (platelet count
This article summarizes the FDA review and the data supporting the approval of ado-trastuzumab emtansine as a component of treatment for patients with HER2-positive EBC with residual disease. PMID: 32217612 [PubMed - as supplied by publisher]
AbstractThrombotic Microangiopathy (TMA) is a heterogeneous collection of syndromes that encompasses TTP, HUS, and other processes characterized by thrombocytopenia, microangiopathic hemolytic anemia, and, if untreated, organ failure and death. Novel therapies have recently been approved for the management of certain thrombotic microangiopathies, including caplacizumab for immune-mediated TTP, and eculizumab for atypical HUS. These options have complicated the standard workflow, which includes initiation of plasma exchange until ADAMTS13 testing can be resulted. Given such results may take several days, there is indecision...
We describe a 25-year-old man with isolated thrombocytopenia initially. He experienced recurrent seizures with stable thrombocytopenia after the first seizures related to intracranial hemorrhage. He was identified a novel c.3452C>T mutation by targeted exome sequencing. If a patient with thrombocytopenia shows recurrent seizures as well as renal, hearing, visual symptoms, MHA should be suspected and the targeted exome sequencing is considered an effective diagnostic tool.